2021 American Transplant Congress
Cognition After Belatacept Conversion (CAB) Trial
1Yale University, New Haven, CT, 2Yale New Haven Hospital, New Haven, CT
*Purpose: Extensive adverse effect profiles including neurotoxicity, manifesting as short-term memory loss, make CNIs less desirable despite their efficacy preventing acute rejection and increasing graft…2020 American Transplant Congress
MTOR-Inhibitor Regimens and Malignancy after Kidney Transplantation: Can the Risk Be Modified by Considering Human Leukocyte Antigen (HLA) Mismatch in Immunosuppression Selection?
*Purpose: We investigated the outcomes of mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs) in categories of donor/recipient pre-transplant…2020 American Transplant Congress
Steroids Ameriplate the Progression of Calcineurin Inhibitors Nephrotoxicity in Kidney Allografts
1Hokkaido University, Sapporo, Japan, 2Sapporo City General Hospital, Sapporo, Japan
*Purpose: Although calcineurin inhibitors (CNI) lead to excellent short-term kidney allograft outcome, chronic nephrotoxicity is a major concern which affects long-term allograft survival. It has…2020 American Transplant Congress
Impact of CYP3A5 Phenotype on Early Time in Therapeutic Range among Pediatric Renal and Heart Transplant Recipients
University of Michigan, Ann Arbor, MI
*Purpose: Tacrolimus time in therapeutic range (TTR) as a measure of intra-patient variability has been associated with poor long-term outcomes. Multiple factors may contribute to…2020 American Transplant Congress
Impact of a Pharmacist Led Outpatient Tacrolimus Monitoring Protocol in Renal Transplant Recipients
Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: The purpose of this study is to compare the time within therapeutic range (TTR) of tacrolimus (TAC) before and after the initiation of a…2020 American Transplant Congress
Comparing Weight-Based Dosing of Envarsus XR in Obese and Non-Obese Renal Transplant Recipients
North Shore University Hospital, Manhasset, NY
*Purpose: Tacrolimus has a narrow therapeutic window and significant inter- and intra-patient variability leading to variations in drug concentration. The recommended initial weight-based dose of…2020 American Transplant Congress
Impact of Concentrations on Conversion from Twice‑Daily to Once‑Daily Tacrolimus in Stable Kidney Graft Recipients: A Single-Center Retrospective Study
Transplant Surgery, Tianjin First Central Hospital, Tian Jin, China
*Purpose: Potential benefits of once-daily tacrolimus include improved adherence to immunosuppressives and decreased Intrapatient variability (IPV) post kidney transplantation. A retrospective analysis was performed to…2020 American Transplant Congress
Pharmacokinetic Evaluation of a De Novo Envarsus XR® (tacrolimus Extended Release) Dosing Strategy in Kidney Transplant Recipients
*Purpose: Envarsus XR® is a once-daily tablet formulation of tacrolimus recently approved for the prophylaxis of organ rejection in de novo kidney transplant recipients (KTx).…2020 American Transplant Congress
Sodium Zirconium Cyclosilicate Use in Solid Organ Transplant Recipients and its Effect on Potassium and Immunosuppression
*Purpose: Transplant recipients often suffer from hyperkalemia which can limit pharmacotherapy. The cause of hyperkalemia is often multifactorial including kidney dysfunction, calcineurin inhibitor use, and…2020 American Transplant Congress
Kidney Transplant Results Comparing Two Formulations of Prolonged-Release Tacrolimus: Paired Study of Kidney Donors
*Purpose: Although the formulations of prolonged-release tacrolimus (Advagraf® and Envarsus®) are effective after kidney transplantation in terms of efficacy and safety, no paired analysis has…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »